

# Elisabetta Vulpis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8863122/publications.pdf>

Version: 2024-02-01

22  
papers

928  
citations

516681

16  
h-index

642715

23  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1508  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interplay of protein corona and immune cells controls blood residency of liposomes. <i>Nature Communications</i> , 2019, 10, 3686.	12.8	160
2	Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF- $\kappa$ B axis. <i>Oncotarget</i> , 2017, 6, e1279372.	4.6	100
3	Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. <i>Journal of Immunology</i> , 2015, 195, 736-748.	0.8	85
4	The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. <i>Oncotarget</i> , 2015, 6, 23609-23630.	1.8	78
5	Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. <i>Journal of Hematology and Oncology</i> , 2016, 9, 134.	17.0	72
6	Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans-Presentation. <i>Cancer Immunology Research</i> , 2018, 6, 860-869.	3.4	59
7	Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy. <i>Human Pathology</i> , 2015, 46, 1760-1768.	2.0	46
8	When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer. <i>Science Advances</i> , 2022, 8, eabj3286.	10.3	35
9	Cancer Exosomes as Conveyors of Stress-Induced Molecules: New Players in the Modulation of NK Cell Response. <i>International Journal of Molecular Sciences</i> , 2019, 20, 611.	4.1	34
10	MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 926.	4.8	33
11	NKG2D Ligand Shedding in Response to Stress: Role of ADAM10. <i>Frontiers in Immunology</i> , 2020, 11, 447.	4.8	30
12	Key Role of the CD56 <sup>low</sup> CD16 <sup>low</sup> Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells. <i>Cancers</i> , 2018, 10, 473.	3.7	29
13	Oponin-Deficient Nucleoproteic Corona Endows UnPEGylated Liposomes with Stealth Properties <i>In Vivo</i> . <i>ACS Nano</i> , 2022, 16, 2088-2100.	14.6	28
14	Targeting NKG2D and Nkp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy. <i>Critical Reviews in Immunology</i> , 2016, 36, 445-460.	0.5	27
15	An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1479-1492.	4.2	22
16	Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12176.	12.2	22
17	Immune complexes exposed on mast cell-derived nanovesicles amplify allergic inflammation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1260-1263.	5.7	18
18	Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2435.	3.7	15

#	ARTICLE	IF	CITATIONS
19	Cancer extracellular vesicles as novel regulators of NK cell response. Cytokine and Growth Factor Reviews, 2020, 51, 19-26.	7.2	13
20	The Possible Role of Sex As an Important Factor in Development and Administration of Lipid Nanomedicine-Based COVID-19 Vaccine. Molecular Pharmaceutics, 2021, 18, 2448-2453.	4.6	11
21	High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma. Leukemia and Lymphoma, 2017, 58, 2493-2496.	1.3	6
22	<i>In vitro</i> and <i>ex vivo</i> nano-enabled immunomodulation by the protein corona. Nanoscale, 2022, 14, 10531-10539.	5.6	3